Company: NCEL
Filing Date: 2025-10-29
Form Type: 6-K
Source: 0001213900-25-103226
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-10-29
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025 (Report No. 6)

Commission File Number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)</div>

Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:

<div align='center'>☒
Form 20-F ☐ Form 40-F

CONTENTS</div>

On
November 4, 2024, NLS Pharmaceutics Ltd. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”)
providing for the merger of NLS Pharmaceutics (Israel) Ltd., a wholly owned subsidiary of the Company, with and into Kadimastem Ltd. (“Kadimastem”),
with Kadimastem surviving as a wholly owned subsidiary of the Company (the “Merger”). At the effective time of the Merger,
each outstanding ordinary share of Kadimastem (the “Kadimastem Ordinary Shares”) will be exchanged for the right to receive
a number of duly authorized, validly issued, fully paid and non-assessable common shares of the Company, determined in accordance with
the exchange ratio set forth in the Merger Agreement (the “Exchange Ratio”).

In
order to effect the transactions contemplated by the Merger Agreement and satisfy applicable Nasdaq initial listing requirements, the
Company’s shareholders were asked to approve certain corporate actions (the “Proposals”). On September 10, 2025, the
Registrant filed with the Securities and Exchange Commission a Registration Statement on Form F-4 (File No. 333-284075) that included
the notice, proxy statement, and form of proxy card for the Extraordinary General Meeting, which was held on September 29, 2025 (the “Meeting”).
The Registration Statement included, among others, the following Proposals: (1) an ordinary capital increase, by way of contribution in